Avigan Oral Antiviral Study Launches in the USA

Appili Therapeutics Inc. announced that investigators have dosed the first participant in its Phase 3 trial (“PRESECO”) evaluating oral Avigan® tablets (favipiravir) for the treatment of COVID-19. Appili is focusing this study in the USA, and expects to report early data from the PRESECO study in the first half of 2021.

Dr. Yoav Golan, Chief Medical Officer, Appili Therapeutics, said in a press release: “Early intervention with patients before they develop severe COVID-19 and require hospitalization remains a significant unmet need in the COVID-19 treatment landscape."

"As is the case with influenza, we believe oral antivirals will play a critical role in treating COVID-19 and preventing its progression. Avigan’s pill format and shelf-life stability make it particularly well-suited for this endeavor," added Dr. Golan.